Insulin detemir, sold under the brand name Levemir among others, is a long-acting insulin used to treat both type 1 and type 2 diabetes.[6] It is used by injection under the skin.[6] It is effective for up to 24 hours.[6]
Common side effects include low blood sugar, allergic reactions, pain at the site of injection, and weight gain.[6] Use in pregnancy and breastfeeding appears safe.[7] It works by increasing the amount of glucose that tissues take in and decreasing the amount of glucose made by the liver.[6]
Insulin detemir was approved for medical use in the European Union in June 2004, and in the United States in June 2005.[5][6][8] In 2018, it was the 112th most commonly prescribed medication in the United States, with more than 6 million prescriptions.[9][10]
Medical use
It is used to treat both type 1 and type 2 diabetes.[6] With respect to blood sugar management, it appears to work at least as well as NPH insulin and insulin glargine.[6]
Side effects
Common side effects include low blood sugar, allergic reactions, pain at the site of injection, and weight gain.[6] Use in pregnancy and breastfeeding appears safe.[7]
Chemistry
It is an insulin analogue in which a fatty acid (myristic acid) is bound to the lysine amino acid at position B29. It is quickly absorbed after which it binds to albumin in the blood through its fatty acid at position B29. It then slowly dissociates from this complex.
Society and culture
On June 13, 2009, the U.S. Food and Drug Administration (FDA) issued a public health advisory for insulin determir after learning that 129,000 stolen vials reappeared and were being sold in the U.S. market. The FDA warned that the stolen vials "may not have been stored and handled properly and may be dangerous for patients to use." The stolen vials were identified as lots XZF0036, XZF0037, and XZF0038.[11]
| This article uses material from the Wikipedia article Metasyntactic variable, which is released under the Creative Commons Attribution-ShareAlike 3.0 Unported License. |